These smart glasses help people with macular degeneration by eliminating blind spots
Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.
Macular Degeneration Treatment Market Size is Projected to Reach USD 18.59 Billion by 2033, Growing at a CAGR of 7.06%: Straits Research
The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...
Managed Healthcare Executive1d
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
FiercePharma1d
Roche gains label expansion for eye implant Susvimo to treat diabetic macular edema
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...
Pharmabiz4h
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
Business Wire1d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Macular Degeneration Treatment Market Size, Top Share, Forecast To 2033
Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...
Daily18h
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...